Outcome data
| . | Early prophylaxis . | Delayed prophylaxis . | P, early vs delayed prophylaxis . | High-titer inhibitor . |
|---|---|---|---|---|
| Participants in analysis, n | 15 (14 with MRI) | 18 | N/A | 4 |
| Age of JOS-C exit, mean (SD) | 17.5 (1.7) | 18.4 (0.3) | .1 | 18.7 (0.2) |
| MRI OC damage, n/N (%) | ||||
| Participants with OC damage | 5/14 (35) | 14/18 (77) | .02* | 2/4 (50) |
| Joints with OC damage | 11/84 (13) | 26/108 (24) | .06 | 3/24 (13) |
| Participants with surgery for hemophilic arthropathy | 1 | 2 | N/A | 0 |
| No MRI damage, eMRI < 1, n/N (%) | ||||
| Participants with no damage | 2/14 (14) | 2/18 (11) | .79 | 0/4 (0) |
| Joints with no damage | 40/84 (48) | 48/108 (44) | .66 | 9/24 (38) |
| eMRI, median (IQR) of participant joint averages | ||||
| eMRI score | 1.3 (0.5-2.2) | 2.3 (1.3-5.0) | .17 | 0.8 (0.7-2.0) |
| OC eMRI score | 0.04 (0-0.8) | 1.2 (0.3-3.1) | .08 | 0 (0-1.0) |
| Lifetime, mean (SD) [median (IQR)] | ||||
| J-ABR | 1.5 (1.2) [1.1 (0.7-2.3)] | 4.3 (3.7) [3.9 (2.4-5.2)] | .007* | 2.0 (1.8) |
| ABR | 3.5 (2.1) [2.7 (2.2-4.7)] | 10.6 (6.6) [9.5 (6.5-11.8)] | <.001* | 7.4 (8.8) |
| After prophy start, mean (SD) [median (IQR)] | ||||
| J-ABR | 1.6 (1.4) [1.1 (0.7-2.6)] | 4.0 (4.6) [2.8 (1.7-4.7)] | <.05* | 2.5 (2.5) |
| ABR | 3.3 (1.9) [2.7 (2.1-4.7)] | 6.2 (5.3) [4.6 (2.4-8.6)] | <.05* | 5.0 (4.3) |
| CPJAS, mean (SD) of participant joint averages | ||||
| Physical examination score | 2.4 (1.6) | 3.2 (2.2) | .23 | 2.4 (1.0) |
| Percent adherence, mean (SD) | 91.5 (9.4) | 82.2 (17.4) | .1 |
| . | Early prophylaxis . | Delayed prophylaxis . | P, early vs delayed prophylaxis . | High-titer inhibitor . |
|---|---|---|---|---|
| Participants in analysis, n | 15 (14 with MRI) | 18 | N/A | 4 |
| Age of JOS-C exit, mean (SD) | 17.5 (1.7) | 18.4 (0.3) | .1 | 18.7 (0.2) |
| MRI OC damage, n/N (%) | ||||
| Participants with OC damage | 5/14 (35) | 14/18 (77) | .02* | 2/4 (50) |
| Joints with OC damage | 11/84 (13) | 26/108 (24) | .06 | 3/24 (13) |
| Participants with surgery for hemophilic arthropathy | 1 | 2 | N/A | 0 |
| No MRI damage, eMRI < 1, n/N (%) | ||||
| Participants with no damage | 2/14 (14) | 2/18 (11) | .79 | 0/4 (0) |
| Joints with no damage | 40/84 (48) | 48/108 (44) | .66 | 9/24 (38) |
| eMRI, median (IQR) of participant joint averages | ||||
| eMRI score | 1.3 (0.5-2.2) | 2.3 (1.3-5.0) | .17 | 0.8 (0.7-2.0) |
| OC eMRI score | 0.04 (0-0.8) | 1.2 (0.3-3.1) | .08 | 0 (0-1.0) |
| Lifetime, mean (SD) [median (IQR)] | ||||
| J-ABR | 1.5 (1.2) [1.1 (0.7-2.3)] | 4.3 (3.7) [3.9 (2.4-5.2)] | .007* | 2.0 (1.8) |
| ABR | 3.5 (2.1) [2.7 (2.2-4.7)] | 10.6 (6.6) [9.5 (6.5-11.8)] | <.001* | 7.4 (8.8) |
| After prophy start, mean (SD) [median (IQR)] | ||||
| J-ABR | 1.6 (1.4) [1.1 (0.7-2.6)] | 4.0 (4.6) [2.8 (1.7-4.7)] | <.05* | 2.5 (2.5) |
| ABR | 3.3 (1.9) [2.7 (2.1-4.7)] | 6.2 (5.3) [4.6 (2.4-8.6)] | <.05* | 5.0 (4.3) |
| CPJAS, mean (SD) of participant joint averages | ||||
| Physical examination score | 2.4 (1.6) | 3.2 (2.2) | .23 | 2.4 (1.0) |
| Percent adherence, mean (SD) | 91.5 (9.4) | 82.2 (17.4) | .1 |
Numbers expressed as mean (SD) or median (IQR) for continuous variables depending on normal or skewed distribution, and number (percentage) for count variables. ABRs were normally skewed but are shown as both mean (SD) and median (IQR) for comparison with other publications. High-titer inhibitor descriptive statistics are also shown. Maximum CPJAS score 31 points, per joint; maximum MRI score, 45 per joint; maximum osteochondral score, 36 per joint.
P < .05 between groups.